Similarities and Differences among Bispecifics: BCMA vs non-BCMA
Medical experts examine differences and similarities in the referral process and treatment protocols for non–BCMA-targeted vs BCMA-targeted bispecific therapies, including aspects like step-up dosing and premedication.
EP: 1.Importance of Collaboration between Academic and Community Centers
EP: 2.Referral Process: Streamlining and Challenges Seen
EP: 3.Referral Process: Bispecifics
Now Viewing
EP: 4.Similarities and Differences among Bispecifics: BCMA vs non-BCMA
EP: 5.Types of Referrals and Impact of Social Factors on the Referral Process
EP: 6.Managing AEs Seen with Bispecifics
EP: 7.Referral Process: CAR T-Cell Therapy
EP: 8.CAR T: Impact of Recent Approvals on the Referral Process
EP: 9.Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care
EP: 10.Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM
Video content above is prompted by the following:
Is the process different/similar for patients who might be receiving non–BCMA-targeted bispecific vs BCMA-targeted bispecific?
Review any differences/similarities between bispecifics (non-BCMA vs BCMA) for step-up dosing, premedication/prophylaxis, etc.
Recent Videos
Related Content
